Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses methods for reliably assessing measurable residual disease (MRD) in patients with multiple myeloma (MM). Dr Paiva highlights that next-generation flow and sequencing (NGF; NGS) techniques are highly reliable for MRD assessment and notes additional prognostic information that can be obtained by flow cytometry. Dr Paiva concludes by emphasizing the need to create new tools to identify unexpected outcomes in patients. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
